सभी अध्ययन
सक्रिय लेकिन भर्ती नहींचरण3हस्तक्षेपात्मक

A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis

This research study is investigating a new medication, Remibrutinib, for adults who have Generalized Myasthenia Gravis. The main aim is to understand if Remibrutinib is effective at helping with the symptoms of this condition, how safe it is, and whether people can tolerate it well. Participants will either receive Remibrutinib or a placebo (a dummy medicine that looks the same but has no active ingredient), in addition to their current, stable treatments. This will be done in a way that neither the patient nor their doctor knows who is getting which treatment at first. The study hopes to gather important information that could help improve future treatment options for Myasthenia Gravis.

एक नजर में

स्थिति
सक्रिय लेकिन भर्ती नहीं
चरण
चरण3
प्रायोजक
नोवार्टिस फार्मास्यूटिकल्स
नामांकन लक्ष्य
180
प्रारंभ
07 Feb 2025
अनुमानित पूर्णता
26 Feb 2033

यह अध्ययन किस बारे में है?

This study is about an illness called Generalized Myasthenia Gravis, which is a long-term condition that causes muscle weakness. It's looking into a new medicine called Remibrutinib. The main goal is to find out if this medicine can help improve symptoms, if it's safe to use, and if people find it easy to take, especially when they're already on their usual treatments.

To do this, some adult patients with Generalized Myasthenia Gravis will receive the new medicine, Remibrutinib, while others will get a placebo. A placebo looks just like the real medicine but contains no active ingredient. This is a common way to test new medicines, as it helps researchers see if any improvements are truly due to the new drug or something else. Neither the patients nor their doctors will know who is receiving which treatment during the first part of the study; this is called 'double-blind'.

Later, everyone will have the chance to take Remibrutinib. The study aims to involve around 180 people and split them into two groups. By carefully comparing the groups, experts hope to learn a lot about Remibrutinib and whether it could become a helpful new treatment option for people living with Generalized Myasthenia Gravis.

मुख्य निष्कर्ष

  • This study is testing a new medicine (Remibrutinib) for Generalized Myasthenia Gravis.
  • It aims to see how well it works and if it's safe.
  • You would continue your existing Myasthenia Gravis treatments.
  • Participants will either receive Remibrutinib or a dummy drug (placebo) at first.
  • The study could last for several years, with regular check-ups.
  • आप किसी भी समय भाग लेना बंद कर सकते हैं।.

कौन पात्र हो सकता है?

This study is looking for adults aged between 18 and 75 who have been diagnosed with Generalized Myasthenia Gravis. Your doctor will need to confirm you have a certain level of Myasthenia Gravis symptoms and are unlikely to need breathing support during the study.

You'll also need to have had specific antibody tests that confirm your Myasthenia Gravis, or show you don't have these antibodies. Your symptoms should include a certain level of daily activity difficulties, with at least half of these difficulties not related to your eyes. You must also be on a steady dose of your current Myasthenia Gravis treatments and be able to swallow the study medication safely.

There are also some reasons why you might not be able to join. For example, if you've recently had certain treatments like IV immunoglobulins, plasma exchange, or specific therapies such as rituximab, eculizumab, or efgartigimod within certain timeframes before the study. Also, if you've had surgery to remove your thymus gland in the last six months or plan to have one, you wouldn't be able to join. Women who could become pregnant must be using effective contraception throughout the study and for a week afterwards.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. Are you an adult between 18 and 75 years old?
  2. Do you have a confirmed diagnosis of Generalized Myasthenia Gravis?
  3. Are your Myasthenia Gravis symptoms mostly affecting parts of your body other than your eyes?
  4. Are you currently on a stable dose of your usual Myasthenia Gravis treatments?
  5. Can you safely swallow medications, as checked by your doctor?
  6. Have you avoided certain other Myasthenia Gravis treatments (like IVIg/PLEX, rituximab, eculizumab, etc.) within specific recent timeframes?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you join this study, it will be split into two main parts. For the first six months, you will either receive Remibrutinib or a placebo, and neither you nor your doctors will know which one. This period involves regular visits to the clinic for assessments and to check how you're feeling and if the treatment is helping.

After these first six months, if you wish to continue, you could then enter an 'open-label' part of the study. This means everyone will receive Remibrutinib, and everyone will know they are receiving the active drug. This longer part could last for up to five years. Throughout the study, you'll have appointments to review your health, check for any side effects, and monitor your Myasthenia Gravis symptoms. The study medication will need to be swallowed, and your ability to do so will be assessed.

संभावित जोखिम और लाभ

Taking part in a study like this might offer a potential benefit if Remibrutinib helps improve your Myasthenia Gravis symptoms more than your current treatment or the placebo. However, there's also a chance you might experience side effects from the new medicine, or that it might not help your symptoms. The research team will carefully monitor you for any changes in your health. Remember, joining any clinical study is always voluntary, and you have the right to withdraw at any time without explaining your reasons, and this will not affect your future medical care.

Locations (120)

  • Neuromuscular Research Center
    सत्यापित पोस्टकोड
    फीनिक्स, संयुक्त राज्य अमेरिका
  • Honor Health Research Institute
    सत्यापित पोस्टकोड
    स्कॉट्सडेल, संयुक्त राज्य अमेरिका
  • Fullerton Neuro and Headache Ctr
    सत्यापित पोस्टकोड
    फुलर्टन, संयुक्त राज्य अमेरिका
  • University Of Southern California
    सत्यापित पोस्टकोड
    लॉस एंजेलेस, संयुक्त राज्य अमेरिका
  • California Pacific Medical Center
    सत्यापित पोस्टकोड
    सैक्रामेंटो, संयुक्त राज्य अमेरिका
  • Medstar Washington Hospital Center
    सत्यापित पोस्टकोड
    वॉशिंगटन डी.सी., संयुक्त राज्य अमेरिका
  • SFM Clinical Research LLC
    सत्यापित पोस्टकोड
    बोका रैटन, संयुक्त राज्य अमेरिका
  • Homestead Assoc In Research Inc
    सत्यापित पोस्टकोड
    Homestead, United States
  • Neurology Associates PA
    सत्यापित पोस्टकोड
    Maitland, United States
  • एडवेंटहेल्थ
    सत्यापित पोस्टकोड
    ऑरलैंडो, संयुक्त राज्य अमेरिका
  • Neurological Services of Orlando PA
    सत्यापित पोस्टकोड
    ऑरलैंडो, संयुक्त राज्य अमेरिका
  • University of Chicago Medical Centr
    सत्यापित पोस्टकोड
    शिकागो, संयुक्त राज्य अमेरिका

सामान्य प्रश्न

What is Generalized Myasthenia Gravis?

It's a long-term condition that causes muscle weakness throughout the body.

What is Remibrutinib?

It's a new medicine being tested to see if it can help people with Myasthenia Gravis.

'प्लेसबो' क्या है?

A placebo is a dummy medicine that looks like the real drug but contains no active ingredients. It's used for comparison.

क्या मुझे पता चलेगा कि मुझे असली दवा मिल रही है या प्लेसीबो?

For the first six months, neither you nor your doctor will know. After that, everyone will get the active medicine.

अध्ययन कितने समय तक चलेगा?

The main part is six months, with an option to continue for up to five years.

और अधिक जानने के लिए कैसे पता करें

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.